Noble Financial Downgrades Evoke Pharma (EVOK) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Rodman & Renshaw Downgrades Evoke Pharma (EVOK) to Neutral
July 18, 2016 11:24 AM EDTRodman & Renshaw downgraded Evoke Pharma (NASDAQ: EVOK) from Buy to Neutral with a price target of $2.00.
For an analyst ratings summary and ratings history on Evoke Pharma click here. For more ratings news on Evoke Pharma click here.
Shares of Evoke Pharma closed at $10.73 yesterday.
... MoreFeltl & Co Downgrades Evoke Pharma (EVOK) to Sell
July 18, 2016 11:21 AM EDTFeltl & Co downgraded Evoke Pharma (NASDAQ: EVOK) from Strong Buy to Sell with a price target of $0.20.
For an analyst ratings summary and ratings history on Evoke Pharma click here. For more ratings news on Evoke Pharma click here.
Shares of Evoke Pharma closed at $10.73 yesterday.
... MoreFBR Affirms Evoke Pharma (EVOK) at 'Outperform' Following EVK-001 Phase 3 Endpoint Miss
July 18, 2016 11:21 AM EDTFBR & Co. affirmed Evoke Pharma, Inc. (NASDAQ: EVOK) with an Outperform rating and $17 price target after the company announced topline results from its Phase 3 clinical trial of EVK-001 in female patients with symptomatic diabetic gastroparesis. In this study, EVK-001, the Company's patented nasal delivery formulation of... More
Brean Capital Downgrades Evoke Pharma (EVOK) to Hold
July 18, 2016 10:55 AM EDTBrean Capital downgraded Evoke Pharma (NASDAQ: EVOK) from Buy to Hold.
For an analyst ratings summary and ratings history on Evoke Pharma click here. For more ratings news on Evoke Pharma click here.
Shares of Evoke Pharma closed at $10.73 yesterday.
... MorePre-Open Stock Movers 07/18: (ARMH) (PRKR) (GRPN) Higher; (EVOK) (FOE) (DDD) Lower (more...)
July 18, 2016 9:31 AM EDTToday's Pre-Open Stock Movers:
Evoke Pharma, Inc. (NASDAQ: EVOK) 74% LOWER; announced topline results from its Phase 3 clinical trial of EVK-001 in female patients with symptomatic diabetic gastroparesis. In this study, EVK-001, the Company's patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adult women, did not achieve its primary endpoint of symptom improvement at Week 4.
Evoke Pharma (EVOK) Says EVK-001 Phase 3 Clinical Trial Didn't Met Primary Endpoint
July 18, 2016 8:32 AM EDTEvoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced topline results from its Phase 3 clinical trial of EVK-001 in female patients with symptomatic diabetic gastroparesis. In this study, EVK-001, the Company's patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adult women, did not achieve its primary endpoint of symptom improvement at Week 4.
Preliminary review of topline data across all study sites revealed similar improvement in the EVK-001 and... More
